Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,590 questions in 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer
current versionsNo studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Number of participants who had to be admitted for post‐procedure bleeding · Women undergoing excision of the cervical transformation zone for cervical neoplasia Antibiotics for infection prevention after excision of the cervical transformation zone (2017) · Cochrane | RR 1.21 [0.52, 2.82] | 2 studies · 638 participants | Very low |
Intervention NR Number of participants who developed fever · Women undergoing excision of the cervical transformation zone for cervical neoplasia Antibiotics for infection prevention after excision of the cervical transformation zone (2017) · Cochrane | RR 2.23 [0.2, 24.36] | 1 study · 290 participants | Very low |
Intervention NR Number of participants who experienced lower abdominal pain · Women undergoing excision of the cervical transformation zone for cervical neoplasia Antibiotics for infection prevention after excision of the cervical transformation zone (2017) · Cochrane | RR 1.03 [0.61, 1.72] | 1 study · 290 participants | Low |
Intervention NR Number of participants who experienced any adverse effects related to antibiotics · Women undergoing excision of the cervical transformation zone for cervical neoplasia Antibiotics for infection prevention after excision of the cervical transformation zone (2017) · Cochrane | RR 1.69 [0.85, 3.34] | 2 studies · 638 participants | Very low |
Intervention NR Number of participants who received additional medical consultant (for any reasons) · Women undergoing excision of the cervical transformation zone for cervical neoplasia Antibiotics for infection prevention after excision of the cervical transformation zone (2017) · Cochrane | RR 2.68 [0.97, 7.41] | 1 study · 290 participants | Low |
Intervention NR Number of participants who had additional self‐medication · Women undergoing excision of the cervical transformation zone for cervical neoplasia Antibiotics for infection prevention after excision of the cervical transformation zone (2017) · Cochrane | RR 1.22 [0.56, 2.67] | 1 study · 290 participants | Very low |
Exposure to any ovary‐stimulating drugs for subfertility vs untreated subfertile women and endometrial cancer risk Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility Risk of endometrial cancer in women treated with ovary‐stimulating drugs for subfertility (2017) · Cochrane | RR 0.96 [0.67, 1.37] | 6 studies · 156774 participants | Very low |
Exposure to any ovary‐stimulating drugs for subfertility vs general population and endometrial cancer risk Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility Risk of endometrial cancer in women treated with ovary‐stimulating drugs for subfertility (2017) · Cochrane | RR 1.75 [1.18, 2.61] | 15 studies · 1762829 participants | Very low |
Exposure to clomiphene citrate for subfertility vs untreated subfertile women and endometrial cancer risk Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility Risk of endometrial cancer in women treated with ovary‐stimulating drugs for subfertility (2017) · Cochrane | RR 1.32 [1.01, 1.71] | 5 studies · 92849 participants | Very low |
Exposure to clomiphene citrate for subfertility vs general population and endometrial cancer risk Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility Risk of endometrial cancer in women treated with ovary‐stimulating drugs for subfertility (2017) · Cochrane | RR 1.87 [1, 3.48] | 4 studies · 19614 participants | Very low |
Exposure to gonadotropins for subfertility vs untreated subfertile women and endometrial cancer risk Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility Risk of endometrial cancer in women treated with ovary‐stimulating drugs for subfertility (2017) · Cochrane | RR 1.55 [1.03, 2.34] | 4 studies · 17769 participants | Very low |
Exposure to gonadotropins for subfertility vs general population and endometrial cancer risk Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility Risk of endometrial cancer in women treated with ovary‐stimulating drugs for subfertility (2017) · Cochrane | RR 2.12 [0.79, 5.64] | 2 studies · 1595 participants | Very low |
Exposure to clomiphene citrate and gonadotropins for subfertility vs untreated subfertile women and endometrial cancer risk Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility Risk of endometrial cancer in women treated with ovary‐stimulating drugs for subfertility (2017) · Cochrane | RR 1.18 [0.57, 2.44] | 2 studies · 6345 participants | Very low |
Exposure to clomiphene citrate and gonadotropins for subfertility vs general population and endometrial cancer risk Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility Risk of endometrial cancer in women treated with ovary‐stimulating drugs for subfertility (2017) · Cochrane | RR 2.99 [1.53, 5.86] | 3 studies · 7789 participants | Very low |
Exposure to GnRH analogues for subfertility vs untreated subfertile women and endometrial cancer risk Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility Risk of endometrial cancer in women treated with ovary‐stimulating drugs for subfertility (2017) · Cochrane | RR 1.21 [0.65, 2.27] | 2 studies · 42558 participants | Very low |
Intervention NR Overall Survival · Adults with recurrent GBM Procarbazine, lomustine and vincristine for recurrent high‐grade glioma (2017) · Cochrane | no estimate extracted | 1 study · 35 participants | Low |
Intervention NR Chemotherapy toxicity · Adults with recurrent GBM Procarbazine, lomustine and vincristine for recurrent high‐grade glioma (2017) · Cochrane | no estimate extracted | 1 study · 35 participants | Very low |
Intervention NR Overall survival median · Adults with recurrent HGG Procarbazine, lomustine and vincristine for recurrent high‐grade glioma (2017) · Cochrane | HR 0.91 [0.74, 1.11] | 1 study · 447 participants | Moderate |
Intervention NR PFS Median · Adults with recurrent HGG Procarbazine, lomustine and vincristine for recurrent high‐grade glioma (2017) · Cochrane | HR 0.89 [0.73, 1.08] | 1 study · 447 participants | Moderate |
Intervention NR QoL EORTC QoL questionnaire C30; at baseline, 12 weeks and 24 weeks · Adults with recurrent HGG Procarbazine, lomustine and vincristine for recurrent high‐grade glioma (2017) · Cochrane | no estimate extracted | 1 study · 415 participants | Low |
Intervention NR Chemotherapy toxicity During 1st 12 weeks of treatment · Adults with recurrent HGG Procarbazine, lomustine and vincristine for recurrent high‐grade glioma (2017) · Cochrane | no estimate extracted | 1 study · 441 participants | Moderate |
Intervention NR PTB (< 37 w) · women with known obstetric outcomes Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive… (2017) · Cochrane | RR 1.75 [1.57, 1.96] | 59 studies · 5242917 participants | Very low |
Intervention NR LBW (< 2500 g) ‐ Treatment versus No Treatment · women with known obstetric outcomes Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive… (2017) · Cochrane | RR 1.81 [1.58, 2.07] | 30 studies · 1348206 participants | Very low |
Intervention NR NICU Admission ‐ Treatment versus No Treatment · women with known obstetric outcomes Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive… (2017) · Cochrane | RR 1.45 [1.16, 1.81] | 8 studies · 2557 participants | Low |
Intervention NR Perinatal Mortality ‐ Treatment versus No Treatment · women with known obstetric outcomes Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive… (2017) · Cochrane | RR 1.51 [1.13, 2.03] | 23 studies · 1659433 participants | Low |
Intervention NR PTB (< 32 to 34 w) · women with known obstetric outcomes Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive… (2017) · Cochrane | RR 2.25 [1.79, 2.82] | 24 studies · 3793874 participants | Very low |
Intervention NR PTB (< 28 to 30 w) · women with known obstetric outcomes Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive… (2017) · Cochrane | RR 2.23 [1.55, 3.22] | 8 studies · 3910629 participants | Very low |
Intervention NR PTB (< 37 w) ‐ Repeat cones versus No Treatment · women with known obstetric outcomes Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive… (2017) · Cochrane | RR 3.78 [2.65, 5.39] | 11 studies · 1317284 participants | Very low |
Intervention NR pPROM (<3 7 w) · women with known obstetric outcomes Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive… (2017) · Cochrane | RR 2.36 [1.76, 3.17] | 21 studies · 477011 participants | Very low |
Intervention NR PTB (< 37 w) ‐ Depth ≤ 10 mm to 12 mm versus No Treatment · women with known obstetric outcomes Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive… (2017) · Cochrane | RR 1.54 [1.09, 2.18] | 8 studies · 550929 participants | Very low |
Intervention NR PTB (< 37 w) ‐ PTB (< 37 w) ‐ Depth ≥10 mm to 12 mm versus No Treatment · women with known obstetric outcomes Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive… (2017) · Cochrane | RR 1.93 [1.62, 2.31] | 8 studies · 552711 participants | Low |
Intervention NR PTB (< 37w) ‐ PTB (<37w) ‐ Depth ≥15 to 17mm versus No Treatment · women with known obstetric outcomes Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive… (2017) · Cochrane | RR 2.77 [1.95, 3.93] | 4 studies · 544986 participants | Very low |
Intervention NR PTB (< 37 w) ‐ PTB (< 37 w) ‐ Depth ≥ 20 mm versus No Treatment · women with known obstetric outcomes Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive… (2017) · Cochrane | RR 4.91 [2.06, 11.68] | 3 studies · 543750 participants | Very low |
Intervention NR Overall mortality · treating infections in people with neutropenia or neutrophil dysfunction Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction (2016) · Cochrane | RR 0.75 [0.54, 1.04] | 6 studies · 321 participants | Very low |
Intervention NR Clinical response to infection · treating infections in people with neutropenia or neutrophil dysfunction Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction (2016) · Cochrane | RR 0.98 [0.81, 1.19] | 5 studies · 286 participants | Low |
Intervention NR Length of time with fever ‐ not reported · treating infections in people with neutropenia or neutrophil dysfunction Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of days on therapeutic antibiotics ‐ not reported · treating infections in people with neutropenia or neutrophil dysfunction Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of serious adverse events ‐ pulmonary · treating infections in people with neutropenia or neutrophil dysfunction Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction (2016) · Cochrane | RR 0.85 [0.38, 1.88] | 1 study · 24 participants | Very low |
Intervention NR Number of adverse events requiring discontinuation of treatment ‐ not reported · treating infections in people with neutropenia or neutrophil dysfunction Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life ‐ not reported · treating infections in people with neutropenia or neutrophil dysfunction Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall survival · Women with newly diagnosed epithelial ovarian cancer Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (2016) · Cochrane | HR 0.81 [0.72, 0.9] | 8 studies · 2026 participants | High |
Intervention NR hearing loss · Women with newly diagnosed epithelial ovarian cancer Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (2016) · Cochrane | RR 0.67 [0.46, 0.99] | 3 studies · 1009 participants | High |
Intervention NR Progression‐free survival · Women with newly diagnosed epithelial ovarian cancer Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (2016) · Cochrane | HR 0.78 [0.7, 0.86] | 5 studies · 1311 participants | High |
Intervention NR Severe adverse effects (G3/4) outcomes · Women with newly diagnosed epithelial ovarian cancer Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR fever · Women with newly diagnosed epithelial ovarian cancer Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (2016) · Cochrane | RR 1.64 [1.13, 2.38] | 5 studies · 1797 participants | High |
Intervention NR fatigue · Women with newly diagnosed epithelial ovarian cancer Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (2016) · Cochrane | RR 2.32 [1.06, 5.07] | 3 studies · 1171 participants | High |
Intervention NR gastrointestinal AEs · Women with newly diagnosed epithelial ovarian cancer Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (2016) · Cochrane | RR 1.71 [1.28, 2.26] | 5 studies · 1339 participants | High |
Intervention NR infection · Women with newly diagnosed epithelial ovarian cancer Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (2016) · Cochrane | RR 3.34 [2.06, 5.43] | 3 studies · 1171 participants | High |
Intervention NR metabolic AEs · Women with newly diagnosed epithelial ovarian cancer Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (2016) · Cochrane | RR 4.45 [2.72, 7.26] | 2 studies · 873 participants | High |
Intervention NR pain · Women with newly diagnosed epithelial ovarian cancer Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (2016) · Cochrane | RR 7.47 [4.41, 12.67] | 3 studies · 1235 participants | High |